HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Disclosure Of Six-Hour Limit Clears Bayer To Claim Aleve ‘Better On Pain’ Than J&J's Tylenol

Executive Summary

An appeals panel in the BBB National Programs, Inc. industry self-regulation program said Bayer should use a "six hour" qualifier with claims that its Aleve naproxen OTC is "better on pain" than J&J's Tylenol acetaminophen products.

You may also be interested in...

NAD Offers Complex And Fast Tracks: Not All Advertising Claim Reviews Are Alike

NAD will assign three attorneys at the beginning of each Complex Track review instead of one, director Laura Brett said in a recent interview. The industry self-regulation group also recently launched its Fast-Track program for more simple ad claim challenges that rarely have been made.

Bayer's Aleve 'Proven Better' Than Tylenol Claims Fail In J&J Challenge At NAD

Bayer appeals to National Advertising Review Board over NAD’s finding the firm didn't support claims its Aleve OTC provides superior pain-relief to J&J’s Tylenol. It says NAD misunderstands scientific data and it will argue pain studies it submitted were methodologically sound and pain-relief statements were not overly broad.

National Advertising Division In Brief

Novartis to discontinue or modify Excedrin claim: Novartis agrees to discontinue or modify its claim that Extra Strength Excedrin will begin to relieve a headache in 15 minutes after the National Advertising Review Board upholds a previous National Advertising Division decision that the firm appealed, NARB says Nov. 24. The appeals division of the Council of Better Business Bureaus reviewed claim-substantiation materials that Novartis submitted to NAD after the firm's express claim for its headache product was challenged by Wyeth, which markets competing headache relief product Advil and has since been acquired by Pfizer (1"The Tan Sheet" March 23, 2009 and 2"The Tan Sheet" Oct. 26, 2009). In March, NAD decided that Novartis' substantiation did not support the claim that the product is the "only gel tab with a triple ingredient formula to start relieving your headache in just 15 minutes." NAD also considered an implied claim the product would provide considerable, if not total, relief in that time. NARB explained that it agrees with NAD's decision that "Novartis did not provide sufficient substantiation for the express claim that Extra Strength Excedrin starts to relieve headache pain in 15 minutes, and recommended that Novartis either discontinue or substantially modify that claim." According to NARB's report, Novartis said it "will, if it uses a similar claim in the future, take NAD's and NARB's conclusions into consideration in formulating and presenting the claim.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts